AU2002239486A1 - Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody - Google Patents

Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody

Info

Publication number
AU2002239486A1
AU2002239486A1 AU2002239486A AU3948602A AU2002239486A1 AU 2002239486 A1 AU2002239486 A1 AU 2002239486A1 AU 2002239486 A AU2002239486 A AU 2002239486A AU 3948602 A AU3948602 A AU 3948602A AU 2002239486 A1 AU2002239486 A1 AU 2002239486A1
Authority
AU
Australia
Prior art keywords
conjuction
chemotherapy
administration
growth factor
radiation therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002239486A
Inventor
Donald J Buchsbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of AU2002239486A1 publication Critical patent/AU2002239486A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002239486A 2000-12-08 2001-12-07 Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody Abandoned AU2002239486A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25178700P 2000-12-08 2000-12-08
US60/251,787 2000-12-08
PCT/US2001/046179 WO2002045653A2 (en) 2000-12-08 2001-12-07 Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody

Publications (1)

Publication Number Publication Date
AU2002239486A1 true AU2002239486A1 (en) 2002-06-18

Family

ID=22953402

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002239486A Abandoned AU2002239486A1 (en) 2000-12-08 2001-12-07 Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody

Country Status (3)

Country Link
US (2) US20020076408A1 (en)
AU (1) AU2002239486A1 (en)
WO (1) WO2002045653A2 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
EP2042194A3 (en) * 1999-05-14 2009-04-22 Imclone Systems, Inc. Treatment of refractory human tumors with epidermal growth factor receptor antagonists
CN101711868A (en) * 2000-05-19 2010-05-26 杰南技术公司 Gene detection assay for improving the likelihood of an effective response to a ErbB antibody cancer therapy
AU2001295002B2 (en) * 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2004282219C1 (en) * 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
AU2005213324B2 (en) * 2004-02-06 2011-06-09 Biogen Idec Ma Inc. Methods and compositions for treating tumors and metastatic disease
CN103007279B (en) * 2004-03-19 2017-01-11 英克隆有限责任公司 Human anti-epidermal growth factor receptor antibody
PT1740591E (en) * 2004-04-02 2009-09-24 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
KR100851271B1 (en) * 2004-06-03 2008-08-08 에프. 호프만-라 로슈 아게 Treatment with irinotecan cpt-11 and an egfr-inhibitor
EP1755608A1 (en) * 2004-06-03 2007-02-28 F.Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
BRPI0511800A (en) * 2004-06-03 2008-01-15 Hoffmann La Roche irinotecan treatment (cpt-11) and an egfr inhibitor
WO2005117916A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
US7449184B2 (en) * 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
CN103432580A (en) 2007-03-02 2013-12-11 健泰科生物技术公司 Predicting response to a HER dimerisation inhibitor based on low HER3 expression
WO2008154249A2 (en) * 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US20100322939A1 (en) * 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
EP2250173A1 (en) * 2008-01-18 2010-11-17 OSI Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
MX2011009729A (en) 2009-03-20 2011-10-14 Genentech Inc Bispecific anti-her antibodies.
JP2012524119A (en) 2009-04-20 2012-10-11 オーエスアイ・ファーマシューティカルズ，エルエルシー Preparation of C-pyrazine-methylamine
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
CN102892779B (en) 2010-02-18 2016-12-21 基因泰克公司 Neuregulin antagonist and the purposes in treatment cancer thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
JP2014526891A (en) 2011-08-17 2014-10-09 ジェネンテック， インコーポレイテッド Neuregulin antibodies and their use
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CA2857114A1 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
MX363188B (en) 2012-11-30 2019-03-13 Hoffmann La Roche Identification of patients in need of pd-l1 inhibitor cotherapy.
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN116333130A (en) 2016-05-24 2023-06-27 英斯梅德股份有限公司 Antibodies and methods of making the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139707A0 (en) * 1998-05-15 2002-02-10 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US6767541B2 (en) * 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways

Also Published As

Publication number Publication date
US20050281814A1 (en) 2005-12-22
WO2002045653A3 (en) 2003-01-03
WO2002045653A2 (en) 2002-06-13
US20020076408A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU2002239486A1 (en) Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
AU4854599A (en) Radiation and nanoparticles for enhancement of drug delivery in solid tumors
AU7490700A (en) Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
AU1337501A (en) Chair and desk system
HUP9901562A3 (en) Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
EE03858B1 (en) Conjugates, their use in prostate cancer drugs, pharmaceutical composition and its preparation
AU2002315168A1 (en) Combination therapy of gamma-interferon and b cell specific antibodies
PL352330A1 (en) Derivatives of pyridopyranoazepine, making of same and use of same in therapy
EP1257565A4 (en) Mucin-1 derived antigens and their use in immunotherapy
AU2003256410A1 (en) COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
EP1558284A4 (en) Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
SG85183A1 (en) Chair with synchronized tilting seat and back
MXPA02007899A (en) Modified cytokines for use in cancer therapy.
AU2001276831A1 (en) Delivery vehicle composition and methods for delivering antigens and other drugs
AU2003227148A1 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
AU4642600A (en) Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells
ZA9610484B (en) New water-swellable preparations of guar and guar derivatives in oleophillic liquids and their use
AU2002216864A1 (en) Conjugates of antibodies and anticancer drugs
IL148936A (en) Use of an agonist and t-cell cytokine receptor antibody in the preparation of a medicament for treating an allergic disorder
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
AU2003291896A1 (en) Saponins and sapogenins for use in combination therapy for cancer
AU1432897A (en) Use of galanthamine in the preparation of novel drugs
AU2824899A (en) Cause, in vitro determination and eradication of cancer
AU3568101A (en) Curative cushion with combined analgesic and relaxing magnetic effects